利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

17 条记录 (耗时 0.047 秒)

    Secondary amino anilinic piperidines as mch1 antagonists and uses thereof
    12.
    发明申请
    Secondary amino anilinic piperidines as mch1 antagonists and uses thereof 失效
    仲氨基苯胺哌啶类作为mch1拮抗剂及其应用

    公开(公告)号：US20050245743A1

    公开(公告)日：2005-11-03

    申请号：US10518675

    申请日：2003-07-03

    申请人： Mohammad Marzabadi ,  Jiang Yu ,  Kai Lu ,  Chien-An Chen ,  John De Leon ,  John Wetzel

    发明人： Mohammad Marzabadi ,  Jiang Yu ,  Kai Lu ,  Chien-An Chen ,  John De Leon ,  John Wetzel

    IPC分类号： A61K31/44 ,  A61K31/451 ,  A61K31/4545 ,  A61K31/506 ,  A61P3/04 ,  A61P13/02 ,  A61P25/22 ,  A61P25/24 ,  A61P43/00 ,  C07D211/26 ,  C07D211/70 ,  C07D401/12 ,  C07D211/68 ,  C07D41/02 ,  C07D43/02

    CPC分类号： C07D211/26 ,  C07D401/12

    摘要： This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compounds of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject=s depression and/or anxiety. This invention further provides a method of treating a subject suffering from a urinary disorder.

    摘要翻译： 本发明涉及作为黑色素浓缩激素-1（MCH1）受体的选择性拮抗剂的化合物。 本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。 本发明提供通过将治疗有效量的本发明化合物与药学上可接受的载体组合而成的药物组合物。 本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物与药学上可接受的载体组合。 本发明还提供减少受试者体重的方法，其包括向受试者施用一定量的有效减少受试者体重的本发明化合物。 本发明进一步提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括向受试者施用有效治疗受试者抑郁症和/或焦虑的量的本发明化合物。 本发明还提供了治疗患有尿失禁的受试者的方法。

    Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
    13.
    发明授权
    Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof 失效
    选择性黑色素浓缩激素-1（MCH1）受体拮抗剂及其用途

    公开(公告)号：US06720324B2

    公开(公告)日：2004-04-13

    申请号：US09899635

    申请日：2001-07-05

    申请人： Mohammad R. Marzabadi ,  John Wetzel ,  John E. DeLeon ,  Bharat Lagu ,  Charles Gluchowski ,  Stewart Noble ,  Dhanapalan Nagarathnam

    发明人： Mohammad R. Marzabadi ,  John Wetzel ,  John E. DeLeon ,  Bharat Lagu ,  Charles Gluchowski ,  Stewart Noble ,  Dhanapalan Nagarathnam

    IPC分类号： C07D23932

    CPC分类号： C07D211/58 ,  C07C233/79 ,  C07C2601/14 ,  C07D211/52 ,  C07D295/073 ,  C07D401/12 ,  C07D401/14 ,  C07D413/14 ,  C07D417/06 ,  C07D471/04 ,  C07D471/10 ,  C07D491/04 ,  C07D491/10

    摘要： This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of modifying feeding behavior of a subject which comprises administering to the subject an amount of a compound of the invention effective to decrease the consumption of food by the subject. This invention further provides a method of treating a feeding disorder in a subject which comprises administering to the subject an amount of a compound of the invention effective to decrease the consumption of food by the subject. In an embodiment of the invention, the feeding disorder is bulimia, bulimia nervosa or obesity.

    摘要翻译： 本发明涉及作为黑色素浓缩激素-1（MCH1）受体的选择性拮抗剂的化合物。 本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。 本发明提供通过将治疗有效量的本发明化合物与药学上可接受的载体组合而成的药物组合物。 本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。本发明还提供了改变受试者进食行为的方法，其包括向受试者施用量 的有效减少受试者食物消耗的本发明化合物。 本发明进一步提供了治疗受试者进食障碍的方法，其包括向受试者施用一定量的有效降低受试者食物消耗的本发明化合物。 在本发明的一个实施方案中，喂食障碍是贪食症，神经性贪食症或肥胖症。

    Processes and polymorphs of diaryl-indolone galr3 antagonists
    14.
    发明申请
    Processes and polymorphs of diaryl-indolone galr3 antagonists 审中-公开
    二芳基 - 吲哚酮galr3拮抗剂的方法和多晶型物

    公开(公告)号：US20050192337A1

    公开(公告)日：2005-09-01

    申请号：US10637214

    申请日：2003-08-07

    申请人： Vrej Jubian ,  John Wetzel ,  Michael O'Neill

    发明人： Vrej Jubian ,  John Wetzel ,  Michael O'Neill

    IPC分类号： C07D209/40 ,  A61K31/404 ,  C07D209/36

    CPC分类号： C07D209/40

    摘要： This invention relates to crystalline forms, as well as an amorphous form of Compound I [1-phenyl-3-[[3-(trifluoromethyl)phenyl]imino]-1H-indol-2-one], the processes for their preparation, compositions containing the same and the therapeutic use of such compositions. This invention further relates to a process for preparing Compound I.

    摘要翻译： 本发明涉及结晶形式，以及化合物I [1-苯基-3 - [[3-（三氟甲基）苯基]亚氨基] -1H-吲哚-2-酮的无定形形式，其制备方法， 含有该组合物的组合物和这些组合物的治疗用途。 本发明还涉及一种制备化合物I的方法。

    3-imino-2-indolones for the treatment of depression and/or anxiety
    15.
    发明申请
    3-imino-2-indolones for the treatment of depression and/or anxiety 有权
    用于治疗抑郁症和/或焦虑的3-亚氨基-2-吲哚酮

    公开(公告)号：US20050148635A1

    公开(公告)日：2005-07-07

    申请号：US11068203

    申请日：2005-02-28

    申请人： Michael Konkel ,  John Wetzel ,  Jamie Talisman

    发明人： Michael Konkel ,  John Wetzel ,  Jamie Talisman

    IPC分类号： C07D209/40 ,  C07D401/04 ,  C07D405/12 ,  C07D43/04 ,  A61K31/4439

    CPC分类号： C07D401/04 ,  C07D209/40 ,  C07D405/12

    摘要： This invention is directed to indolone derivatives which are selective antagonists for the GalR3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety. This invention also provides a method of treating depression and/or anxiety in a subject which comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a GalR3 receptor antagonist.

    摘要翻译： 本发明涉及作为GalR3受体的选择性拮抗剂的吲哚酮衍生物。 本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。 本发明还提供通过将治疗有效量的本发明化合物和药学上可接受的载体组合而制备的药物组合物。 本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。 本发明还提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括给予受试者一定量的有效治疗受试者的抑郁症和/或焦虑症的本发明化合物。 本发明还提供了治疗受试者的抑郁症和/或焦虑症的方法，其包括向受试者施用包含药学上可接受的载体和治疗有效量的GalR3受体拮抗剂的组合物。